SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

The FDA issued a Complete Response Letter for ivonescimab in the EGFR-mutated lung cancer setting, citing the lack of a statistically significant overall-survival benefit despite strong progression-free-survival results. Traders are reacting to the setback with heavy bearishness, while some bulls argue the broader thesis now rests on HARMONi-3 and Summits other trials and partnerships.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is drawing attention ahead of the Phase 3 APPROACH topline readout for HLP003 in major depressive disorder, a closely watched binary catalyst. Traders are hopeful the results will validate the drugs potential, while others emphasize the risk of disappointing data and debate dilution, execution, and competition in the psychedelic-treatment sector.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxiss Investor Day launch plans for ulixacaltamide and relutrigine are drawing attention ahead of two closely spaced FDA decisions. Traders are broadly optimistic about the drugs commercial potential and preparation for launch, while some caution that approval and timing remain uncertain, particularly for relutrigine after the review extension.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,112,050. The last known price of Bitcoin is 63,437.21016941 USD and is down -7.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $45,086,253,428.50 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and volatile rebound are dominating discussion, with traders debating whether oversold conditions and support will bring a recovery or whether further declines are ahead. Some attribute the pressure to liquidations, ETF selling, or Binance-related concerns, but those explanations remain speculation in the conversation.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is drawing attention ahead of its quarterly earnings report, with traders weighing a recent share-price rally against concerns about weak home-improvement demand, falling customer transactions, and high borrowing costs. The debate centers on whether resilient spending per visit and managements outlook can offset a sluggish housing market; options activity also reflects uncertainty about the earnings reaction.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

The FAAs nationwide ground stop following an air-traffic-control communications outage has put Delta in focus, with continuing delays and cancellations raising concerns about operational and earnings impacts. Traders disagree on whether the disruption is a temporary setback or a larger risk, while speculation about its cause remains unverified.

JasmyCoin (JASMY) is a cryptocurrency launched in 2016and operates on the Ethereum platform. JasmyCoin has a current supply of 50,000,000,000 with 49,444,999,677.16957912 in circulation. The last known price of JasmyCoin is 0.00312867 USD and is down -5.82 over the last 24 hours. It is currently trading on 374 active market(s) with $10,034,947.48 traded over the last 24 hours. More information can be found at https://www.jasmy.co.jp/en_company.html.

JasmyCoin

JASMYs prolonged weakness and choppy price action are driving debate: some holders are buying dips and watching for a reversal, while skeptics point to poor performance, limited visible adoption, and Janctions stronger run as reasons for concern. Some traders also attribute the pressure to a broader crypto-market downturn; no single confirmed catalyst dominates.

Cardano (ADA) is a cryptocurrency launched in 2017. Cardano has a current supply of 44,994,648,344.194204 with 36,816,370,531.313927 in circulation. The last known price of Cardano is 0.14666837 USD and is down -12.66 over the last 24 hours. It is currently trading on 1753 active market(s) with $480,085,527.58 traded over the last 24 hours. More information can be found at https://www.cardano.org.

Cardano

Cardanos prolonged weakness has fueled debate over Charles Hoskinsons comments that the networks roadmap is complete: bears read them as a sign the project is being abandoned, while supporters say development is shifting to the community and continue buying the dip. Traders also point to broader crypto-market weakness and bearish price action, with some expecting further declines and others anticipating a rebound.

Shiba Inu (SHIB) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Shiba Inu has a current supply of 589,495,699,860,951.91490568 with 589,238,106,731,035.4551592 in circulation. The last known price of Shiba Inu is 0.00000379 USD and is down -10.85 over the last 24 hours. It is currently trading on 1128 active market(s) with $78,538,817.41 traded over the last 24 hours. More information can be found at https://shibatoken.com/.

Shiba Inu

SHIBs weak, choppy trading and continued decline are drawing attention, with traders pointing to bearish chart signals and waning meme-coin hype. Frustrated holders see more downside, while some dip buyers remain hopeful for a recovery or renewed rally.

iShares Inc. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

South Korean equities are drawing attention amid a sharp, volatile KOSPI selloff, which traders link to an unwind in the AI-memory trade and forced selling from leveraged positions; Samsung and SK Hynixs large index weights amplify the exposure. The community is split between expecting more downside and viewing the pullback as a buying opportunity given continued memory demand and low valuations.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$TTM 
​The Setup: Classic Breakout. The stock has broken out of a 4-week consolidation phase on the daily chart with a massive volume spike.
​News Catalyst: Reported a 22% YoY jump in JLR (Jaguar Land Rover) wholesales, beating street estimates. Additionally, the demerger process of its commercial and passenger vehicle segments is entering the final regulatory phase.
​Technical Level: Bullish above ₹1,045. The 21-day EMA is sloping upward, providing a safety net for swing traders.
​Target/Resistance: ₹1,120.

StockTwits For Android 

 
​The Setup: Classic Breakout. The stock has broken out of a 4-week consolidation phase on the daily chart with a massive volume spike.
​News Catalyst: Reported a 22% YoY jump in JLR (Jaguar Land Rover) wholesales, beating street estimates. Additionally, the demerger process of its commercial and passenger vehicle segments is entering the final regulatory phase.
​Technical Level: Bullish above ₹1,045. The 21-day EMA is sloping upward, providing a safety net for swing traders.
​Target/Resistance: ₹1,120.